Capricor Therapeutics Inc
Symbol: CAPR (NASDAQ)
Company Description:
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Today's Open: $7.21
- Today's High: $7.874
- Today's Low: $7.18
- Today's Volume: 1.39M
- Yesterday Close: $7.21
- Yesterday High: $7.64
- Yesterday Low: $7.1108
- Yesterday Volume: 943.63K
- Last Min Volume: 5
- Last Min High: $7.75
- Last Min Low: $7.75
- Last Min VWAP: $7.75
- Name: Capricor Therapeutics Inc
- Website: https://www.capricor.com
- Listed Date: 2002-06-20
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001133869
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $329.62M
- Round Lot: 100
- Outstanding Shares: 45.72M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-23 | EFFECT | View |
2025-09-10 | S-3 | View |
2025-08-11 | 10-Q | View |
2025-08-11 | 8-K | View |
2025-07-29 | SCHEDULE 13G | View |
2025-07-11 | 8-K | View |
2025-06-16 | S-8 | View |
2025-05-27 | 8-K | View |
2025-05-14 | 10-Q | View |
2025-05-13 | 8-K | View |
2025-04-30 | SCHEDULE 13G/A | View |
2025-04-09 | ARS | View |
2025-04-08 | DEF 14A | View |
2025-04-08 | 8-K | View |
2025-03-26 | 10-K | View |
2025-03-19 | 8-K | View |
2025-03-05 | 4 | View |
2025-03-04 | 4 | View |
2025-03-04 | 4 | View |
2025-03-04 | 4 | View |